期刊文献+

阿比特龙原料药有关物质方法学研究 被引量:2

Relative Substances Test of Abiraterone by HPLC
原文传递
导出
摘要 目的:建立高效液相色谱测定阿比特龙原料药(乙酸阿比特龙酯)有关物质的方法,对乙酸阿比特龙酯原料药中具体杂质做一个定量的控制。方法:采用Luna C18色谱柱(250 mm*4.6 mm,5μm),流动相为甲醇-乙腈-水梯度洗脱,运行时间为60 min,检测波长220 nm,柱温40℃,流速1 m L/min。结果:乙酸阿比特龙酯与有关物质分离度良好,空白溶剂不干扰乙酸阿比特龙酯及其有关物质的检出;杂质A、杂质B、杂质C、杂质D、杂质E、杂质F分别在0.413~14.45μg·m L-1(r=0.9996),0.420~14.71μg·m L-1(r=0.9997),0.398~13.98μg·m L-1(r=0.9996),0.450~15.74μg·m L-1(r=0.9999),0.394~13.79μg·m L-1(r=0.9995),0.387~13.54μg·m L-1(r=0.9998)范围内峰面积呈良好的线性关系;平均加样回收率(n=9)分别为:98.14%,99.34%,99.65%,100.27%,86.21%,97.64%,RSD分别为2.91%,2.59%,1.99%,1.69%,0.91%,3.68%(n=9)。最低检测限分别为:0.04、0.09、0.03、0.07、0.02、0.12μg·m L-1。结论:本方法灵敏度高,操作简便准确,重复性好,适用于乙酸阿比特龙酯有关物质检查。 Objective: To establish an HPLC method for the determination of related substances of Abiraterone acetate,make an quantitative control for the impurities of Abiraterone acetate. Methods: Luna C18 column(250 mm*4.6 mm, 5 μm), the mobile phase was methanol-acetonitrile-water eluted gradiently at the rate of 1.0 m L·min-1. The rnning time was 60 min, the detection wavelengths was220 nm, and the column temperature was 40 ℃. Results: The linear ranges were 0.413 ~14.45 μg·m L-1(r=0.9996)for impurity A,0.420~14.71 μg·m L-1(r=0.9997)for impurity B, 0.398~13.98 μg·m L-1(r=0.9996)for impurity C, 0.450~15.74 μg·m L-1(r=0.9999)for impurity D, 0.394~13.79 μg·m L-1(r=0.9995)for impurity E, 0.387~13.54 μg·m L-1(r=0.9998)for impurity F, respectively.The average recoveries(n=9) of the six components were 98.14%, 99.34%, 99.65%, 100.27%, 86.21% and 97.64%,with RSDs of 2.91%,2.59%, 1.99%, 1.69%, 0.91% and 3.68%(n=9), respectively.The detection limits was 0.04, 0.09, 0.03, 0.07, 0.02, 0.12 μg·m L-1.Conclusion: This method was accurate, rapid, sensitive with high repeatability,which is more suitable for the determination of related substances of Abiraterone acetate.
出处 《现代生物医学进展》 CAS 2015年第28期5418-5423,共6页 Progress in Modern Biomedicine
基金 四川省科技支撑计划项目(2013SZ0084)
关键词 乙酸阿比特龙酯 有关物质 高效液相色谱法 Abiraterone acetate Related substances HPLC
  • 相关文献

参考文献20

  • 1安迪,李洪玉,李金岭,姜申德.阿比特龙醋酸酯的合成[J].化学试剂,2013,35(2):124-126. 被引量:4
  • 2Purushottamachar P, Godbole A M,Gediya L K, et al. SystematicStructure Modifications of Multitarget Prostate Cancer DrugCandidate Galeterone To Produce Novel Androgen ReceptorDown-Regulating Agents as an Approach to Treatment of AdvancedProstate Cancer[J].Med Chem, 2013,56(12): 4880-4898.
  • 3Rowlands M G, Barrie S E, Chan F, et al. Esters of 3-pyridylacetic acidthat combine potent inhibition of 17- alpha-hydroxylasc /Cl7,20-lyase (cytochrome P450 17 alpha )with resistance to cstrasehydrolysis[J].Med Chem, 1995,38(21): 4191-4197.
  • 4Sonpavde G, Attard G, Bellmunt J, et al. The role of abirateroneacetate in the management of prostate cancer :a critical analysis ofthe literature[J].Eur Urol, 2011, 60(2): 270-278.
  • 5Bryce A, Ryan C J. Development and clinical utility of abirateroneacetate as an androgen synthesis inhibitor [J].Clin Pharmacol Ther,2012,91 (1): 101-108.
  • 6Attard G, Reid A H, A Hem R, et al. Selective inhibition of CYP17with abiraterone acetate is highly active in the treatment ofcastration-resistant prostate cancer [J].J Clin Oncol, 2009,27(23): 3742-3748.
  • 7Logothetis C J, Efstathiou E, Manuguid F, et al. Abiraterone acetate[J].Nat Rev Drug Discov, 2011,10(8): 573-574.
  • 8Attard G, De Bono J S. Translating scientific advancement into clinicalbenefit for castration-resistant prostate cancer patients[J].Clin CancerRes, 2011,17(12):3867-3875.
  • 9Debono J S, Logothetis C J, Molina A, et al. Abiraterone and increasedsurvival in metastatic prostate cancer [J].N Engl J Med, 2011,364(21): 1995-2005.
  • 10祁宝辉,宫平.醋酸阿比特龙酯[J].中国药物化学杂志,2011,21(5):407-407. 被引量:12

二级参考文献56

  • 1邢念增,王国栋.晚期前列腺癌治疗的新靶点[J].中华临床医师杂志(电子版),2011,5(18):5253-5255. 被引量:6
  • 2US Food and Drug Administration. FDA approves Zytiga for late-stage prostate cancer [ EB/OL ]. [ 2011 - 04 - 28 ]. http ://www. fda. gov/NewsEvents/N nouncements/ucm253055, htm.
  • 3POTTER G A, BARRIE S E, JARMAN M, et al. Novel steroidal inhibitors of human cytochrome P45017a ( 17α-hydroxylase-CIT.20-1yase) :potential agents for the treatment of prostatic cancer[ J]. J Med Chem, 1995,38 ( 13 ) :2463 - 2471.
  • 4BURY P S. Process for the preparation of 17-0-vinyl-triflates as intermediates : WO,2006/021777A1 [ P]. 2006 - 03 - 02.
  • 5AGARWAJ N, HUTSON T E, VOGELZANG N J, et al. Abiraterone acetate:a promising drug for the treatment of castra- tion-resistant prostate cancer [ J ]. Future Oncol, 2010,6 ( 5 ) : 665 - 679.
  • 6Rajfer J, Sikka SC, Rivera F, et al. Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole EJ]. J Clin Endocrinol Metab, 1986, 63:1193-1198.
  • 7Potter GA, Barrie SE, Jarman M, et al, Novel steroidal inhibitors of human cytochrome P45017ct (17ct-hydroxylase- C17,20-1yase) : potential agents for the treatment of prostatic cancer [J]. JMedChem, 1995, 38(13) : 2463-2471.
  • 8Potter GA, Hardcastle IR. Synthesis of 17-(3-pyridyl)- steroids: WO, 9509178 [P]. 1995-04-06. (CA 1995, 123: 112515).
  • 9Nadia MS, Monika E, Stanley MR, et al. Some regioselective cross-coupling reactions of halopyridines and halopyrimidines [J]..1 Chem Soc Perkin Trans I, 2002, 16: 1847-1849.
  • 10Haidar S, Hartmann R W. C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibi- tors of 17a-hydroxylase-C17,20-1yase : Synthesis and biological evaluation [ J ]. Arch Pharm, 2002,335 ( 11 -12) :526 -534.

共引文献25

同被引文献9

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部